This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Oct 2010

New Vivitrol approval's a big boost for Alkermes

Alkermes has won the FDA nod to promote its alcoholism treatment Vivitrol as an aid for patients hooked on opioids, including prescription painkillers and heroin.

There's now a prescription drug approved to treat prescription drug addiction. Alkermes has won the FDA nod to promote its alcoholism treatment Vivitrol as an aid for patients hooked on opioids, including prescription painkillers and heroin. Addiction-recovery experts are hailing the approval as a possible "game changer" that could keep patients on the wagon after they leave rehab treatment centers.

It could be a game-changer for Alkermes, too. Although the company has been marketing Vivitrol since 2006, it's still not bringing in enough revenues to cover its costs on the drug. Together with just one other marketed product, Alkermes posted $20.2 million in net sales for fiscal 2010, Reuters reports.

With the new indication, Leerink Swann analyst Steve Yoo tells Bloomberg that the opioid-addiction use is "critical for commercial success of the drug." As Reuters notes, Yoo has predicted Vivitrol sales of up to $125 million by 2015, provided it won FDA approval for broa

Related News